BIXT (Bioxytran) EBIT per Share: $-0.02 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioxytran EBIT per Share?

Bioxytran BIXT +7.35% EBIT per Share is $-0.02 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, Bioxytran ranks worse than 66.58% on this metric.

Bioxytran's EBIT per Share for the three months ended in Mar. 2026 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 3.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was 2.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bioxytran's EBIT per Share or its related term are showing as below:

BIXT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -228.1   Med: 34   Max: 92.2
Current: 3.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bioxytran was 92.20% per year. The lowest was -228.10% per year. And the median was 34.00% per year.

BIXT's 3-Year EBIT Growth Rate is ranked worse than
66.58% of 1173 companies
in the Biotechnology industry
Industry Median: 15.5 vs BIXT: 3.10

Bioxytran's EBIT for the three months ended in Mar. 2026 was $-2.01 Mil.

Bioxytran  (OTCPK:BIXT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bioxytran EBIT per Share Related Terms

Bioxytran EBIT per Share Historical Data

* Premium members only.

The historical data trend for Bioxytran's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioxytran EBIT per Share Chart

Bioxytran Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.02 -0.03 -0.01 -0.02

Bioxytran Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.00 -0.00 -0.00 -0.02

Bioxytran EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bioxytran's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.937/91.843
=-0.02

Bioxytran's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.008/112.283
=-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.02 mean?
Bioxytran (BIXT) has a EBIT per Share of $-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioxytran and its competitors. According to the industry distribution chart, Bioxytran ranks #781 out of 1173 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Bioxytran's EBIT per Share too high?
Bioxytran's current EBIT per Share is $-0.02. Based on the distribution chart, Bioxytran ranks #781 out of 1173 companies in the Biotechnology industry, which is below the industry midpoint.
How does Bioxytran's EBIT per Share compare to SPRC and ACUT?
According to the Biotechnology industry distribution chart, Bioxytran ranks #781 out of 1173 companies for EBIT per Share. This places Bioxytran in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bioxytran and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioxytran's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxytran stock overvalued right now?
Bioxytran (BIXT) has a current EBIT per Share of $-0.02. The current EBIT per Share is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bioxytran (BIXT), the current EBIT per Share is $-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioxytran Business Description

Address 75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.